Cessatech A/S publishes annual report for the fiscal year 2020
Cessatech A/S (“Cessatech” or the “Company”) hereby publishes its annual report for the fiscal year 2020. The annual report including the auditor’s report is attached as a pdf. The report is also available on Cessatech’s website www.cessatech.com under ‘Fillings & Reports’.
Full year 2020 (6 April – 31 December):
- Net revenue was KDKK 0
- Operating result was KDKK -901
- Net result was KDKK -849
- Cash and bank was KDKK 13,506
- Result per share* was DKK -0.55
- Solidity** at end of the period was 99%
Highlights during Q2-2020
-
Established the company, the legal entity (6. APR)
- Building the initial organization of consultants and core team
- Finalizing the agreement with Rigshospitalet for CT001
Highlights during Q3-2020
- The complete Board of Directors assembled and assigned
- The manufacturing process for CT001 was finalized
- Finalized selection of preferred Clinical Research Organization (CRO)
Highlights during Q4-2020
- Approval for IPO listing and significantly oversubscribed by approx. 680%
- Finalized negotiations of preferred manufacturer for clinical and commercial batches
- Submitted Fast-track US patent application for CT001
- Initiated clinical preparations of first 3 clinical activities related to CT001
- Trading in Cessatech’s shares and warrants commenced on the Spotlight Stock Market
- Finalization of the Registry Study (0203) from Karolinska University Hospital